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Introduction 
The concept of ethical treatment of hu- 
man subjects has a long and constantly 
evolving history. Its roots are found in 
ancient Anglo common law, but it was 
not until the 20th century, as the abuses 
inflicted on research participants came 
to light, that it attained the importance it 
holds today. Currently, all studies in- 
volving humans are subject to extensive 
regulations, requiring the project to be 
approved by an institutional review 
board ORB)-a body charged with pro 
tecting the patients rights while foster- 
ing valid and methodologically sound 
research.’ Informed consent-the 
prime component of the process by 
which the patient is provided informa- 
tion to make a determination as to 
whether to participate in any experimen- 
tal therapy or process-must be ad- 
dressed for each project. The purpose of 
this paper is to address broadly issues 
regarding ethics and prehospital re- 
search, focusing on informed consent. 
Historical Perspective 
The history of informed consent with 
respect to treatment was first com- 
mented on by Plato, who believed that 
the physician should expressly not dis- 
cuss care with the patient. He stated, 
‘You are not healing the sick man, but 
you are educating him, and he does not 
want to be made a doctor but to get 
we11.“2 Ancient law expanded this con- 
cept, but provided minimal human 
rights protection and limited the au- 
thority of the physician to treat only 
those who requested it. However, on 
this request, which was considered to 
be implied by any person presenting to 
the physician, the patient could be sub- 
jected to all treatment the doctor 
deemed necessary without the right to 
withdraw from or even inquire about 
the therapy being rendered. 
Modern ethical issues have their 
roots in Anglo-American common law, 
which “forbid harmful or offensive non- 
consensual touching, however benign 
in motive or physical effect without 
their consent.” Here, the first definition 
of assault-a threat of approach, battery 
and touching intentionally-came into 
use. The only exception was in emer- 
gency situations. The content of con- 
sent was not defined, it was interpreted 
very broadly, and could take the form of 
actions, words, or be implied from the 
circumstances. The first case law oc- 
curred in 1914, when Supreme Court 
Justice Cardoso ruled that “Every hu- 
man being of adult years and sound 
mind is entitled to determine what is to 
be done with his own body.“3 Despite 
this, ethical issues and informed con- 
sent remained poorly defined and were 
left to the judgment of the researcher. 
A series of horrific situations changed 
all that, and brought the issues into fo- 
cus, eventually leading to our current 
regulations. 
The first event was the revelation of 
the Nazi atrocities in World War II in 
the name of research uncovered during 
the Nuremberg trials. This led to the 
development of the Nuremberg Code in 
1949, which became the cornerstone of 
current research ethics.4 Five main con- 
cepts are at the heart of the code: 
1. Voluntary consent by the re- 
search subject 
2. Explanation of all potential haz- 
ards 
3. The research produces fruitful re 
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Criteria for Institutional 
Review Board Approval 
1, Risks to the patient are minimized. 
2. Risks are reasonable in relation of benefits, including the benefit of knowledge 
gained. 
3. Equitable subject selection. 
4. Informed consent sought and documented. 
5. Privacy of the subjects is maintained strictly. 
6. Ongoing monitoring of data to ensure safety. 
7. Safeguards are included to protect the rights and welfare of vulnerable subjects. 
sults for the good of society former is to ensure sound, ethical and 
4. Valid animal-model based studies valuable research. The responsibility 
5. Each subject can stop the experi- for subject welfare is placed squarely on 
ment at any time. the shoulders of the researcher. It also 
This code spawned a major develop recommended strict accuracy of data/ 
ment of case law, and while the vast ma- results in the publication, with a prohi- 
jority concerned medical practice, the bition against unethical research being 
rulings and principles are generally published. The Belmont Report is a 
thought to hold true for research con- more detailed analysis of basic ethical 
sent. To summarize, consent deals with principles for both medical practice and 
the ethical principle of respect for per- research. The first deals with respect 
sons. The consent process, in theory, is for persons, recognizing an individual’s 
supposed to ensure that the researcher right to self-determination and protect- 
will respect the subject to be self-deter- ing those with diminished autonomy 
mining and able to make independent through the process of informed con- 
free choices. Unless the person allows it, sent. The next principle, beneficence, 
the investigator is not allowed to violate strives to maximize benefit while mini- 
this tenet and touch or enter their pri- mizing possible risks. This is to be 
vate space. The traditional legal view of guaranteed through careful, stringent, 
violation of this principle and failure to and systematic assessment of risks and 
obtain adequate consent is battery. benefits for each study. Justice, or the 
Whether or not harm results is irrele- principle of fairness with respect to the 
vant. More recent case law treats failure distribution of benefit, as well as burden 
to obtain consent as negligence. Negli- of research, is determined through fair 
gence expands on the previous legal selection processes that pay close atten- 
view and brings in the concept of stan- tion to possible bias concerning sex, 
dard therapy and whether the treatment race, societal and cultural issues. 
is deviating from standard therapy (as in While these developments were a 
all experimental research). If so, then positive step in aiding ethical research 
failure to obtain proper informed con- practices, the onus to ensure they were 
sent may be treated as a negligent ac- applied properly was still left entirely to 
tion. The traditional components of a the researcher. A series of incidents 
negligent action may then apply (duty, would soon change this and bring swift 
breach, damage and casualty). In both and vociferous protests from both pub- 
doctrines, the consent is held to be in- lit and scientific communities. A suc- 
valid if any information thought to be cession of highly unethical studies was 
necessary or impo~ant in the subject’s publicized, the most famous of which 
decision-making process is withheld. was the Tuskeegee Syphilis study, in 
Additionally, it is incumbent on the re- which a group of African-American 
searcher to prove the subject has males infected with the disease contin- 
grasped the material prior to consenting. ued to be observed for effects to study 
A brief mention also should be made the natural course of the disease, even 
concerning two further ethical codes- after treatment (penicillin) became 
the Declaration of Helsinki and the available.2$7 Other studies injected el- 
Belmont Reports<6 The thrust of the derly patients with cancer cells without 
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their knowledge, and intentionally ex- 
posed mentally impaired patients to 
Hepatitis A.2 The concept of the benev- 
olent researcher always striving to pro- 
tect the study subjects was forever 
shattered, and led to the current strin- 
gent regulations overseeing human re- 
search. 
lnstit~ional Review Boards 
In 1966, the U.S. Public Health Service 
mandated that all federally funded re- 
search involving human subjects re- 
quires review by a “committee of 
insti~tional associates.“1,7 The mission 
of this committee was to ensure that the 
autonomy of the subject was respected, 
that a well-defined benefit would result 
from this research, and that vulnerable 
subjects (e.g., children or prisoners) 
would be protected. This initiated the 
widespread adoption of the institutional 
review board (IRB). The IRB concept 
was further developed in the early 1970s 
when the Public Health Service re- 
quired peer review for any research sup 
ported by Department of Health 
Education and Welfare grants. Subse- 
quent to this, a series of congressional 
hearings was held in 1974 and estab- 
lished the requirement for IRBs at all 
institutions receiving any federal 
grants, and established the National 
Commission for the Protection of 
Human Subjects of Biomedical and 
Behavioral Research. The code of fed- 
eral regulations was revised in 1983 and 
was adopted by the Department of 
Health and Human Services (DHHS) 
Office for Protection for Research Risks 
(OPRR) .I This set the criteria necessary 
for IRB approval (Table 1). These are 
general guidelines, and each IRB has 
specific instructions as to the form and 
content of each research proposal. This 
is available from each individual IRB of- 
fice. The directive also lists specific 
steps on how to carry out the process of 
reviewing research to ensure that it 
meets the standards. It is important to 
note that the IRB has been given the 
right to preview all qualifying research 
proposals to ensure these criteria are 
met and that a valid study will result. 
Institutional review boards vary in 
their procedures. Most require that the 
investigator submit a written proposal 
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and standardized request forms for re- 
view by the committee. Although all t-e 
search should be submitted through the 
IRB process, some projects will be clap 
sified by the IRB as minimal risk and, as 
a result, receive an expedited review. 
Types of research that may be classiiied 
as minimal risk are chart reviews and 
anonymous surveys. Although the inves- 
tigator may be confident that the study 
is minimal risk and, thus, does not re- 
quire IRB approval, all proposals should 
be submitted for review and patient 
confidentiali~. This places the responsi- 
bility for the review on the IRB, minimiz- 
ing investigator responsibility should 
the study be inappropriately classified as 
exempt from review. 
The process for an expedited review 
varies across institutions but often in- 
volves review by a single staff member 
rather than by the entire committee. 
Because an expedited review does not 
involve the entire committee, the time 
needed to complete the review is short- 
ened. Investigators should determine 
the time needed to obtain the appropri- 
ate IRB approval early in the planning 
stages of the project. 
The next step in dealing with the IRB 
is to decide whether the proposed study 
meets the criteria for full committee re 
view. The definition of this states the IRB 
has jurisdiction in “all research ~vol~ng 
human subjects conducted, supported or 
otherwise subject to regulation by any 
federal department or agency.“1 Also, all 
human-subject research performed in an 
institution with written DHSS-approved 
assurances applies. Put simply, any 
study involvement that performs or al- 
ters any human intervention must be 
IRB approved. There are also other con- 
siderations that each individual IRB may 
want to review for proper confidentiality, 
institutional or personal liability or other 
potential problems. These regulations 
concerning each particular IRB can be 
obtained from the IRB office. 
Suggestions for dos and don’ts when 
dealing with the IRE3 are listed in Table 
2. The interaction between the re- 
searcher and the TRB is an involved 
process. Attempts to properly interact 
with the IRB members for both educa- 
tion and explanation purposes can yield 
dramatic results and greatly improve the 
DOS and Don’ts for Interacting with the 
Institutional Review Board 
Do: 
Design a good project 
Know intricate details of the project 
Show concern for protecting your patients 
Use lay language in consent forms and presentation 
Allow realistic time for review and modification 
Know individual IRB members 
Acquaint the chairperson with your protocol 
Don’t: 
Argue with the IRB 
Submit a proposal in an improper form 
Use technical language 
Disregard patient rights and protection 
Submit a proposal at the last minute 
Be unfamiliar with any aspect of a project 
project. However, this process takes 
time, and it is unrealistic to believe that 
each proposal will be approved on its ini- 
tial submission. The investigator must 
understand that the IRB has a diftlcult 
job, and that board members are trying 
to ensure good and proper research and 
not trying to delay the project. 
Air transport programs that are not as- 
sociated with a single health-care organi- 
zation or academic institution and have 
not received federal funding may not 
have an official IRB. Because of the pro- 
tection offered to the researcher by the 
IRB, such programs may wish to associ- 
ate themselves with a sponsoring hospi- 
tal or develop their own procedures for 
review of proposed investigations. 
Multi-center research presents addi- 
tional challenges to obtaining IRB ap- 
proval. The principal investigator and 
project coordinator at all data collection 
sites must obtain IRB approval at their 
respective institutions. This require- 
ment can create difficulties when two 
IRBs have inconsistent requirements of 
the investigators. A common area of dif- 
ficulty lies in the consent form. In- 
dividual institutions may require specific 
words to be placed in their consent 
forms, and these requirements may be 
in direct conflict with one another. If in- 
consistent consent forms are required, 
the researcher may be served best by 
having the subjects sign two consent 
forms-the one from the institution of 
the principal investigator and the one 
from the insti~tion where data are be- 
ing collected on that subject. Subject 
consent forms may be kept at the insti- 
tution where the data are collected or all 
may be stored by the principal investiga- 
tor. In either case, the consent forms 
must be available for review by federal 
or other agencies on request. 
Informed Consent 
The cornerstone of each IRB proposal 
and the area most scrutiniied is that of 
informed consent. Without adequate 
preparation and attention to this area, 
the research proposal will not gain the 
necessary approval from the IRB. 
Absence of approp~ate informed con- 
sent also opens the researcher and the 
sponsoring institution to civil liability.8 
To obtain valid informed consent, 
four basic tenets must be rnet.QJ,s The 
first is that the subject has adequate de- 
cision-making capacity, including a 
proper emotional state that allows a de 
cision to be made. The patient must be 
legally competent and under no coer- 
cion. Finally, all relevant information 
must be disclosed in an understandable 
manner to the subject. Several points 
deserve explanation. Many ethicists feel 
that the process of reviewing the con- 
sent with the patient is inherently 
flawed, especially if a physician is partic- 
ipating and does not allow the subject to 
make a free choice. There are many 
motives for patients to participate in re- 
search one is to please the reviewer, a 
factor that can become magnified when 
it is the physician who reviews the con- 
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Department of Health and Human Services 
Consent Waiver Requirements 
1. The research could not practicably be carried out without the waiver. 
2. Whenever appropriate, the subject will be provided with additional, pertinent infor- 
mation after participation. 
3. The research involves no more than minimal risk. 
4. The waiver will not affect adversely the rights and welfare of the subject. 
Food and Drug Administration 
Consent Waiver Requirements 
1. Subject is confronted by a life-threatening situation, necessitating the experimental 
therapy. 
2. Informed consent cannot be obtained from the subject due to an inability to commu- 
nicate or obtain legally effective consent from the subject. 
3. Insufficient time to obtain consent from the subject’s legal representative. 
4. There is no reliable alternative method of approval therapy that provides an equal or 
greater likelihood of saving the life of the subject. 
sent. However, unlike a normal busi- 
ness contract in which the burden of 
understanding is on the consumer, here 
the responsibility lies with the re- 
searcher. Imagine if when you purchase 
a car, the dealer was required to inform 
you of all the possible faults of the auto. 
This is the situation with research. 
The next process is the actual admin- 
istration of the consent, which is also 
well-defined.7 The first step is inform- 
ing. This is a detailed 16-step process 
that dictates the key elements of infor- 
mation that must be communicated to 
the subject. While each step is not valid 
for every project, the basic framework 
must be followed. Next is an assessment 
of the subject’s comprehension of the 
presented material, and proof of under- 
standing may be required. Interestingly, 
the material needs only to be under- 
stood at the time of presentation, not in 
the future. Following this, an assess- 
ment of the subject’s autonomy must be 
conducted, and he or she must not be 
under any undue stress. The last step is 
the demonstration by the prospective 
participant of a willingness to partici- 
pate, which forms the actual act of con- 
senting. In the majority of cases, this 
includes the completion of a written 
form with a signature, although other 
methods may be acceptable. 
There are a number of problems with 
the classical approach to consent, partic- 
ularly in the prehospital setting. Re- 
search into the consent procedures, and 
how it is accepted by patients, has 
demonstrated that research subjects of- 
ten do not understand the process, and 
may sign the form for such reasons as 
believing it necessary to receive treat- 
ment, or to please the researcher.8 
When they do understand the purpose, 
they often prefer to have the decision 
made by the physician. In the prehospi- 
tal setting, practical considerations limit 
the utility of traditional informed con- 
sent. First, the process is lengthy and 
time consuming. Second, it requires a 
competent and understanding patient 
and a qualitied person to administer the 
consent (usually a physician). Obviously, 
these requirements would exclude the 
majority of patients and, therefore, most 
EMS research. A directive, issued in 
1993 by the OPRR, mandates that all hu- 
man studies approved by an IRH require 
prospective informed consent from the 
patient or patient representative. In re- 
sponse to the acknowledged hardship on 
emergency research, a meeting has 
been convened by the Food and Drug 
Administration (FDA) and the National 
Institutes of Health to obtain public and 
scientitic input on the impact of consent 
regulations on emergency research. 
Until these issues are resolved, waiver 
regulations exist. 
There are two sets of waiver regula- 
tions-one each issued by the De- 
partment of Health and Human Services 
(DHSS), the other by the FDA.2 The 
first (DHSS) permits a waiver if the IRB 
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“finds and documents” four conditions 
(See Table 3). The first point is easily 
satisfied by the acute nature of prehospi- 
tal illness, qualification of those applying 
the consent and the time constraints es 
sentially preventing traditional consent. 
Many therapies are also time-depen- 
dent. Point two presents little problem 
and point four must be addressed by en- 
suring any preference of the patient is 
strictly honored, such as an advance di- 
rective. 
The most difficult and complex idea 
involves the “condition of minimal risk.” 
Minimal risk is defined as the risk of 
harm anticipated in the proposed re- 
search not being greater than those or- 
dinarily encountered in daily life or 
during the performance of routine phys- 
ical or psychological exams or tests. 
Thus, the experimental therapy should 
not entail more than this additional risk 
when compared to standard therapy. 
This definition has limited utility, as 
many of the disease processes studied 
in the prehospital setting, especially in 
air medical transport, (such as cardiac 
arrest, trauma and shock) inherently 
have poor outcome regardless of the 
therapy applied. 
The second set of waiver regulations 
is provided through the FDA and gov- 
ems research on unapproved drugs and 
devices (Table 4). Points one through 
three are usually easily satisfied, while 
point four may present problems. If any 
physician feels certain that one therapy 
is superior, he or she is permitted 
(some would say ethically bound) to 
use this therapy. Therefore, some have 
objected to the randomization process, 
in which a patient cannot predict which 
therapy he or she will receive. In such 
cases, there must be a real question 
about which treatment is superior, re- 
gardless of individual opinion. History 
has shown the need for objective re- 
search studies, despite anecdotal expe- 
rience and opinions to be contrary. 
Even when there is thought to be a 
“clear” advantage to a particular ther- 
apy, in as many as 50% of cases this 
preference has proven incorrect when 
formally studied.2 
There also has been significant dis- 
cussion about the concept of deferred 
consent.3 This has been used in the set- 
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ting of resuscitation research in which 
the patient is enrolled into the study 
without approval from the subject or 
family. Once the subject is stabilized 
and the initial experimental therapy ini- 
tiated, the family is approached for tra- 
ditional informed consent. At that point, 
the family may choose to discontinue 
the experimental treatment. This alter- 
native is currently not an option as de- 
termined in the 1993 OPRR directive. 
This leaves only two options: informed 
consent or waiver. 
In light of the traditional waiver re- 
quirement and the changing ideas and 
concerns surrounding consent, the FDA 
has put forth a new set of proposed 
guidelines titled, “Exception from 
Informed Consent for Emergency 
Research.“10 This both condenses and 
expands on the previous two waiver reg- 
ulations (Iable 5). There must be a real 
question about current therapy, and 
valid scientific evidence, which may in- 
clude that obtained through randomized 
trials, should be necessary to determine 
which intervention is most beneficial. No 
practical way can exist to obtain in- 
formed consent at the time of interven- 
tion, and prospective obtainment of 
consent is not feasible because the emer- 
gence of the condition being studied can- 
not be predicted reliably in particular 
individuals. The risk must be deter- 
mined to be reasonable in light of what is 
known about the medical condition and 
the risks and benefits of both the current 
and interventional therapy. The in- 
creased provision for public disclosure 
and involvement makes the researchers 
responsible to the community in which 
the research is being performed and also 
provides input from a viewpoint that may 
not be considered routinely during pro 
posal development. Consultation may be 
initiated by the IRB. Finally, although 
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